Navigation Links
Biomodels Expands Efforts in Cancer Supportive Care, Pulmonary Fibrosis; Preclinical Research Organization Names Dr. Stephen T. Sonis as Partner
Date:7/22/2009

WATERTOWN, Mass., July 22 /PRNewswire-USNewswire/ -- Biomodels LLC, a pre-clinical research organization best known for its expertise in oral mucositis, today announced it will further increase its work in the areas of cancer supportive care, pulmonary fibrosis, and biphosphonate-related osteoncrosis, with the promotion of Stephen T. Sonis DMD, DMSc to partner.

Dr. Sonis, a world-renowned expert in the clinical treatment and research of cancer regimen-related mucosal toxicities, said the company's collaborative work with pharmaceutical and biotechnology clients in the area of cancer supportive care is expected to grow sharply this year.

"The side effects of cancer treatment are becoming increasing important, as pharmaceutical and biotechnology companies realize that more effective dosing regimens can be achieved if side effects are considered and ameliorated at the pre-clinical stage," Dr. Sonis said.

Biomodels (www.biomodels.com) researchers have identified common mechanisms underlying toxicities that can lead to more rapid pharmaceutical interventions.

"Few people have the opportunity to help take a molecule from inception to patients, especially patients with great clinical need," Dr. Sonis said. "Biomodels' success in assisting industry to make the transition from test tube to the clinic as smoothly, quickly, safely and predictably as possible has been exciting for me.

"I look forward to our continued development of innovative models that expedite the clinical development process, especially to meet the challenges posed by regimen-related toxicities of cancer therapy," he added.

Biomodels is internationally known for its work in developing predictive animal models that are helping to determine which patients are predisposed to mucositis, osteonecrosis, cancer treatment-related thrombosis, gastrointestinal toxicity, pulmonary fibrosis, and salivary gland changes.

Dr. Sonis is widely recognized for his studies on the molecular and cellular pathogensis of mucositis, which have resulted in identifying a number of promising pharmaceutical targets to alleviate this universal and incapacitating side of effects of cancer treatment.

He has served as chief medical officer of Biomodels since it was founded in 1997, and holds appointments with the Harvard School of Dental Medicine, the Dana-Farber Cancer Institute, and Brigham and Women's Hospital.

He is the author of more than 100 original publications, 40 reviews and chapters, and seven books. Dr. Sonis serves on a number of editorial boards, and is a founding member of the International Society of Oral Oncology.

About Biomodels

Biomodels (www.biomodels.com), a preclinical contract research organization founded in 1997, has developed and conducted preclinical studies for biotechnology and pharmaceutical companies, particularly in the areas of cancer, cancer supportive care, radiation, therapy, and inflammatory diseases.

The company specializes in (non-GLP) predictive studies that evaluate efficacy and define mechanism of action, enabling clients to expedite the drug discovery process. Biomodels' preclinical studies anticipate clinical objectives and enable organizations to rapidly achieve preclinical milestones.

Photo available upon request.


'/>"/>
SOURCE Biomodels LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ATS Medical Expands Open Pivot Heart Valve Offerings
2. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
3. BioLife Solutions Expands Scientific Advisory Board
4. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
5. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
6. Pharsight Expands Strategic Consulting Services Team
7. Validus Pharmaceuticals Expands Product Portfolio with Acquisition of Bipolar Drug: Equetro(R)
8. Serica Technologies Expands Facilities in Massachusetts, Combines State-Of-The-Art Textile Engineering and Biomedical Manufacturing
9. AQUISS Expands Into Significant New Territory
10. NanoBio Expands Drug Development Team for Its Anti-Infective Products
11. BitWine (TM) Nutrition Advisors Network Expands Roster of Licensed Dietitians and Nutritionists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , ... December 02, 2016 , ... Robots will storm ... on December 3rd, 2016. The event, which is held on the United Nations ... helping Americans with Disabilities back into the workplace. Suitable Technologies is partnering with NTI ...
(Date:11/30/2016)... CLEVELAND , Nov. 30, 2016  GenomOncology today announced ... Vice President of Medical Affairs.  Dr. Coleman ... enhancing the company,s proprietary knowledge-enabled platform. The GenomOncology software suite ... of genetic sequencing data and clinical decision support, from quality ... , ...
(Date:11/30/2016)... /PRNewswire/ -  Equicare Health Inc ., the leading supplier ... one of the top 100 companies in the 2016 ... distinguishes the top digital health companies across the globe. ... this year continually upgrading our product with the ongoing ... team," says Len Grenier , CEO of Equicare ...
(Date:11/30/2016)... Mass. , Nov. 30, 2016   Merck ... that it has entered into a set of agreements ... services for Merck,s collection of genetic reagents such as ... with Evotec,s screening expertise offers an accelerated pathway to ... discovery starts with the identification of new targets, a ...
Breaking Biology Technology:
(Date:11/30/2016)... 30, 2016 Not many of us realize that we spend ? of ... we need to do it well. Inadequate sleep levels have been found to lead ... diabetes, and even cancer. Maybe now is the best time to rethink ... them to manage their sleep quality? Continue Reading ... ...
(Date:11/29/2016)... BOSTON , Nov. 29, 2016 BioDirection, ... rapid point-of-care products for the objective detection of concussion ... the company has successfully completed a meeting with the ... company,s Tbit™ blood test Pre-Submission Package. During the meeting ... Tbit™ system as a precursor to commencement of a ...
(Date:11/29/2016)... -- Nearly one billion matches per second with DERMALOG,s high-speed ... ... DERMALOG is Germany's largest Multi-Biometric supplier: ... (PRNewsFoto/DERMALOG Identification Systems) ... is Germany's largest Multi-Biometric supplier: The company's Fingerprint Identification System is part ...
Breaking Biology News(10 mins):